

---

# Kluwer Patent Blog

## USA: Endo Pharmaceuticals Inc. v. Actavis Laboratories UT, Inc, United States Court of Appeals, Federal Circuit, No. 2016-1146, 14 October 2016

Jody Coultas (CCH) · Tuesday, October 25th, 2016

Actavis Laboratories UT, Inc. was unable to show that patents licensed to Endo Pharmaceuticals Inc. covering its testosterone gel product Fortesta® were invalid as obvious in light of prior art, according to the U.S. Court of Appeals for the Federal Circuit. Therefore, a district court ruling finding that the patents were not obvious was affirmed (Endo Pharmaceuticals Inc. v. Actavis Laboratories UT, Inc., October 14, 2016, Taranto, R.).

A [full summary](#) of this case has been published on [Kluwer IP Law](#).

---

*To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).*

### Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how [Kluwer IP Law](#) can support you.

---

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.**

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT  
The Wolters Kluwer Future Ready Lawyer  
Leading change



This entry was posted on Tuesday, October 25th, 2016 at 8:00 am and is filed under [Pharma](#), [United States of America](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.